

Cancer Immunotherapy 2004

Thursday, May 6

Thursday, May 6

8:30-8:45 Welcoming Adress
C. Huber, Mainz

Workshop 1: "ANTIBODY THERAPY"

Chairpersons: B. Dörken, Berlin; M. Gramatzki, Erlangen

8:45-9:00 Introduction by B. Dörken and M. Gramatzki

9:00-9:30 "Disrupting signaling pathways with anti-ErbB receptor antibodies:
biological and clinical implications"
J. Albanell, Barcelona, Spain

9:30-10:00 „Mechanisms of killing by anti-cancer antibodies“
M. Glennie, Southhamptom, United Kingdom

10:00-10:30 **Coffee Break**

10:30-10:45 "Bispecific costimulatory molecules for activation of tumor-killing
lymphocytes"
R. Weth, Frankfurt/Main, Germany

10:45-11:00 "Antibody-based immunoreceptors: the impact of signalling domain,
binding affinity and costimulation"
H. Abken, Cologne, Germany

11:00-11:15 "Tolerability and efficacy of the trifunctional antibody removab[®]
(anti-EpCAM x anti-CD3) in patients with malignant ascites due to
ovarian cancer: Results of a phase I/II study"
P. Wimberger, Essen, Germany

11:15-11:30 "HLA DR-directed bispecific single-chain Fv antibodies for lymphoma
therapy"
Y. Wachter, Erlangen, Germany

11:30-11:45 NN

11:45-12:15 **Round Table and Conclusion**

12:15-12:55 Poster visits

12:55-13:45 **Lunch**

Cancer Immunotherapy 2004

Thursday, May 6

Workshop 2: "IMMUNE ESCAPE MECHANISMS / NK CELL RECOGNITION"

Chairpersons: A. Knuth, Zürich; B. Seliger, Halle

- 13:45-14:00 Introduction by A. Knuth and B. Seliger
- 14:00-14:30 "MHC antigens and tumor immune escape"
F. Garrido, Granada, Spain
- 14:30-15:00 "Induction of protective T cell responses by activated NK cells"
R. Mocikat, Munich, Germany
- 15:00-15:15 "Increased frequency of CTLA4+ TGFbeta+ CD4+ CD25+ T cells in peripheral blood of patients with chronic lymphatic leukemia and multiple myeloma"
M. Beyer, Cologne, Germany
- 15:15-15:30 "MMP-7 inhibits CTL - tumor cell interaction"
S. Gregor, Mainz, Germany
- 15:30-16:00 **Coffee Break**
- 16:00-16:15 "Genetically modified natural killer cells specifically recognizing the tumor-associated antigens ErbB2/HER2 and EpCAM"
C. Uherek, Frankfurt/Main, Germany
- 16:15-16:30 "Rapid functional exhaustion and deletion of cytotoxic T lymphocytes following immunization with recombinant adenovirus"
E. Scandella, St. Gallen, Switzerland
- 16:30-16:45 "High frequency of functionally active Melan-A specific T cells in a patient with progressive immunoproteasome-deficient melanoma"
A. Mackensen, Regensburg, Germany
- 16:45-17:15 **Round Table and Conclusion**
- 17:15-17:45 Poster visits

Special Lecture

- 17:45-18:30 "Pitfalls and remedies in the exploitation of therapeutic T-cell immunity against cancer"
C.J.M. Melief, Leiden, Netherlands

Cancer Immunotherapy 2004

Friday, May 7

Workshop 3: ADOPTIVE T CELL TRANSFER

Chairpersons: A. Mackensen, Regensburg; M. Theobald, Mainz

- 08:30-8:45 Introduction by A. Mackensen and M. Theobald
- 08:45-9:15 "T Cell Transfer Therapy"
M. Dudley, Bethesda, USA
- 09:15-9:45 "The Influence of T Cell Receptor Genes on Tumor Cell Recognition"
M. Nishimura, Chicago, USA
- 09:45-10:15 **Coffee Break**
- 10:15-10:30 "Adoptive T cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma: a phase I clinical study"
A. Mackensen, Regensburg, Germany
- 10:30-10:45 "Large Scale In Vitro Expansion of Polyclonal Human CD4+CD25high Regulatory T Cells"
P. Hoffmann, Regensburg, Germany
- 10:45-11:00 "Reversible HLA multimers (streptamers) for isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens"
J. Neudorfer, Munich, Germany
- 11:00-11:15 "Therapeutic efficacy of RAGE-1 and MAGE-9 peptide specific cytotoxic T cell clones in renal cell carcinoma"
N. Oehlrich, Heidelberg, Germany
- 11:15-11:30 "The role of glycosylation as a modulator for signalling strength in T cells"
B. Hauptrock, Mainz, Germany
- 11:30-12:00 **Round Table and Conclusion**
- 12:00-12:40 Poster Visits
- 12:40-13:30 **Lunch**

Cancer Immunotherapy 2004

Friday, May 7

Workshop 4: THERAPEUTIC VACCINATION

Chair: G. Schuler, Erlangen; T. Wölfel, Mainz

- 13:30-13:45 Introduction by G. Schuler and T. Wölfel
- 13:45-14:15 "Specific immunotherapy of cancer: Identification, functional and molecular characterization of tumor reactive cytolytic T lymphocytes"
P. Romero, Lausanne, Switzerland
- 14:15-14:45 "DC Vaccination - where do we stand? Results of a prospective randomized trial."
D. Schadendorf, Mannheim, Germany
- 14:45-15:00 "Migration of Dendritic Cells regional lymph nodes in a vaccination trial"
A. Riccobon, Forlì, Italy
- 15:00-15:15 "Transitory response to vaccination with PSCA-/PSA-Peptide loaded, autologous dendritic cells in patients with metastatic, hormon-refractory prostate cancer"
A.K. Kaskel, Freiburg, Germany
- 15:15-15:35 **Coffee Break**
- 15:35-15:50 "Vaccination with WT1 induces high frequency memory and effector T cells in peripheral blood and bone marrow associated with complete remission of recurrent AML"
A. Letsch, Berlin, Germany
- 15:50-16:05 "LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers"
A. Bender, Frankfurt/Main, Germany
- 16:05-16:20 "Tumor vaccination after allogeneic bone marrow cell reconstitution of the non-myeloablatively conditioned tumor-bearing murine host"
M. Zöller, Heidelberg, Germany
- 16:20-16:50 **General Discussion and Conclusion**
- 16:50-17:00 Final Remarks
H.-G. Rammensee